8-K: Rafael Holdings Reports Q2 Fiscal 2025 Results; Merger with Cyclo Therapeutics Expected to Close in Q3

Rafael Holdings reported its Q2 fiscal year 2025 financial results and anticipates closing its merger with Cyclo Therapeutics in Q3, with a strategic focus on Trappsol Cyclo post-merger.

Summary

• Rafael Holdings reported its financial results for the second quarter and first six months of fiscal year 2025, which ended January 31, 2025.
• The company anticipates closing its merger with Cyclo Therapeutics in Q3, pending shareholder approvals.
• Post-merger, the company intends to focus on Trappsol Cyclo, its lead clinical program.
• As of January 31, 2025, Rafael Holdings had cash and cash equivalents of $48.3 million.
• For the three months ended January 31, 2025, the company recorded a net loss attributable to Rafael Holdings of $4.6 million, or $0.19 per share, compared to net income of $6.0 million, or $0.25 per fully diluted share, in the year-ago period.
• The year-over-year decline was attributed to unrealized losses on investments in Cyclo equity and convertible notes receivable.
• Research and development expenses were $0.9 million for the three months ended January 31, 2025, compared to $0.6 million in the year-ago period.
• For the six months ended January 31, 2025, the company recorded a net loss attributable to Rafael Holdings of $13.6 million, or $0.57 per share, compared to net income of $2.4 million, or $0.10 per share, in the year-ago period.
• The year-over-year decline was attributed to unrealized losses on investments in Cyclo and convertible notes receivable.
• Research and development expenses were $2.3 million for the six months ended January 31, 2025, compared to $1.1 million in the year-ago period.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reported a net loss, they are optimistic about the upcoming merger and the potential of Trappsol Cyclo. The focus on a specific clinical program could be a positive step.

Positives

• The company has $48.3 million in cash and cash equivalents as of January 31, 2025.
• The company is optimistic about the potential of Trappsol Cyclo to treat Niemann-Pick Disease Type C1.
• Preliminary results from the Phase 3 TransportNPC Open-Label Sub-Study are encouraging.

Negatives

• The company recorded a net loss of $4.6 million for the three months ended January 31, 2025, compared to net income of $6.0 million in the year-ago period.
• The company recorded a net loss of $13.6 million for the six months ended January 31, 2025, compared to net income of $2.4 million in the year-ago period.
• The year-over-year decline in net income was attributed to unrealized losses on investments in Cyclo equity and convertible notes receivable.

Risks

• The company's future performance is subject to risks and uncertainties, including those disclosed in its filings with the SEC.
• The company's forward-looking statements are subject to known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially from those expressed or implied.

Future Outlook

The company anticipates closing its merger with Cyclo Therapeutics in Q3 2025 and will focus on Trappsol Cyclo as its lead clinical program post-merger. Topline data from the 48-week interim analysis of the Trappsol Cyclo study is expected in the middle of 2025.

Management Comments

• 'Upon closing, the Company's strategic focus will be on its lead clinical asset, Trappsol Cyclo,' said Bill Conkling, CEO of Rafael Holdings.
• Bill added, 'We are encouraged by the preliminary results presented at the 21st Annual WORLDSymposium in early February from the ongoing Phase 3 TransportNPC Open-Label Sub-Study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1 in patients <3 years of age.'

Industry Context

Rafael Holdings' focus on Trappsol Cyclo for Niemann-Pick Disease Type C1 aligns with the industry's growing interest in rare disease therapeutics. The merger with Cyclo Therapeutics is a strategic move to consolidate resources and expertise in this area.

Comparison to Industry Standards

• It is difficult to compare Rafael Holdings directly to industry standards due to its holding company structure and diverse portfolio.
• However, the focus on rare disease therapeutics is a common strategy among smaller pharmaceutical companies seeking to address unmet medical needs.
• Cyclo Therapeutics is a direct competitor to other companies developing therapies for Niemann-Pick Disease Type C, such as Orphazyme (now bankrupt) and Mallinckrodt.

Stakeholder Impact

• Shareholders will be impacted by the merger with Cyclo Therapeutics and the company's strategic focus on Trappsol Cyclo.
• Patients with Niemann-Pick Disease Type C1 may benefit from the development of Trappsol Cyclo.
• Employees of Rafael Holdings and Cyclo Therapeutics will be affected by the merger.

Next Steps

• Shareholder vote on the pending merger with Cyclo Therapeutics.
• Closing of the merger with Cyclo Therapeutics in Q3 2025.
• Focus on Trappsol Cyclo as the lead clinical program.
• Release of topline data from the 48-week interim analysis of the Trappsol Cyclo study in mid-2025.

Key Dates

Keywords

Rafael Holdings, Cyclo Therapeutics, Merger, Trappsol Cyclo, Niemann-Pick Disease Type C1, Financial Results, Q2 2025, Pharmaceuticals, Clinical Trials, Investment